Gemzar (Pancreatic cancer) – Analysis and Forecasts to 2020

Gemzar (Pancreatic cancer) – Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “Gemzar (Pancreatic cancer) - Analysis and Forecasts to 2020” provides Gemzar sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2015). The report also includes information on Pancreatic Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Gemzar including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Gemzar including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecasts from 2002-2015 for Gemzar in the seven major markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 4
2.1 Pancreatic Cancer 4
2.2 Pancreatic Cancer Market 4
2.3 Epidemiology 4
2.4 Etiology 7
2.4.1 Cigarette Smoking 7
2.4.2 Age 7
2.4.3 Gender 8
2.4.4 Family History 8
2.4.5 Other Factors 8
2.5 GlobalData Market Forecasts Report Guidance 9
3 Pancreatic Cancer: Market Characterization 10
3.1 Pancreatic Cancer Market 10
3.2 Pancreatic Cancer Market Forecasts and CAGR 10
3.3 Drivers for Pancreatic Cancer Market 11
3.3.1 High Prevalence 11
3.3.2 High Incidence 11
3.3.3 Large Unmet Need 12
4 Tumor-Node-Metastases (TNM) Classification of Pancreatic Cancer 13
5 Gemzar 16
5.1 Introduction 16
5.2 Mechanism of Action 16
5.3 Clinical Studies 16
5.4 Approval History of Gemzar 17
5.5 Factors Affecting Sales of Gemzar 17
5.5.1 Generic Erosion 17
5.5.2 High Efficacy 17
5.5.3 Standard Care of Treatment 17
5.6 Drug Risk Benefit Score 18
5.6.1 Efficacy 18
5.6.2 Safety 18
5.6.3 Compliance 18
5.6.4 Dosing Convenience 18
5.7 Intensity of Competition 18
5.8 Sales Forecast 19
5.8.1 Target Patient Pool of Gemzar 19
5.8.2 Dosing 20
5.8.3 Market Penetration 20
5.8.4 Annual Cost of Therapy 20
5.8.5 Sales Projections of Gemzar 21
6 Pancreatic Cancer Market: Appendix 31
6.1 Market Definitions 31
6.2 List of Abberiviations 31
6.3 Research Methodology 32
6.3.1 Coverage 32
6.3.2 Secondary Research 32
6.3.3 Forecasting 32
6.3.4 Number of Patients Approved to take the Drug 33
6.3.5 Net Penetration of Drug 33
6.3.6 Net Annual Dosing 34
6.3.7 Annual Cost of Therapy 34
6.3.8 Primary Research 34
6.3.9 Expert Panels 35
6.4 Contact Us 35
6.5 Disclaimer 35
6.6 Sources 35